Estradiol Levels in Patients Treated With Estring

Inclusion Criteria

• •Stage I-III estrogen receptor positive breast cancer (positive for estrogen receptor (ER)) with positivity defined as immunohistochemical staining in ≥ 10% of cells) on adjuvant hormonal therapy with aromatase inhibitors (anastrozole, letrozole or exemestane)
• •Adults over 18 years of age with a life expectancy of at least 3 months
• •Attained menopause as defined by World Health Organization Criteria (defined as permanent cessation of menstruation resulting from the loss of ovarian follicular activity. This is recognized to occur after 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause.)
• •Persistent genitourinary symptoms causing discomfort for more than 2 weeks prior to the visit with the physician.
• •Tried at least 1 prior pharmacological/ non-pharmacological treatment for their genitourinary symptoms
• •Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to any study specific procedures
• •Be willing and able to comply with the treatment plan, scheduled clinic visits, laboratory tests and other study procedures